Optimization of an Experimental Vaccine to PreventEscherichia coliUrinary Tract Infection

Abstract

<jats:title>Abstract</jats:title><jats:p>Urinary tract infections (UTI) affect half of all women at least once during their lifetime. The rise in extended-spectrum beta-lactamase-producing strains and potential for carbapenem resistance within uropathogenic <jats:italic>Escherichia coli</jats:italic> (UPEC), the most common causative agent of UTIs, creates an urgent need for vaccine development. Intranasal immunization of mice with UPEC outer membrane iron receptors, FyuA, Hma, IreA, or IutA, conjugated to cholera toxin, provides protection in the bladder or kidneys when challenged with UPEC CFT073 or 536. Based on these data, we sought to optimize the vaccination route (intramuscular, intranasal, or subcutaneous) in combination with adjuvants suitable for human use including alum, monophosphoryl lipid A (MPLA), unmethylated CpG synthetic oligodeoxynucleotides (CpG), polyinosinic:polycytodylic acid (polyIC), and mutated heat-labile <jats:italic>E. coli</jats:italic> enterotoxin (dmLT). Mice intranasally vaccinated with dmLT-IutA or dmLT-Hma displayed a significant reduction in bladder colonization (86-fold and 32-fold, respectively) with 40–42% of mice having no detectable colony forming units (CFU). Intranasal vaccination of mice with CpG-IutA and polyIC-IutA significantly reduced kidney colonization (131-fold) and urine CFU (22-fold), respectively. dmLT generated the most consistently robust antibody response in intranasally immunized mice, while MPLA and alum produced greater concentrations of antigen-specific serum IgG with intramuscular immunization. Based on these results, we conclude that intranasal administration of Hma or IutA formulated with dmLT adjuvant provides the greatest protection from UPEC UTI. This study advances our progress toward a vaccine against uncomplicated UTI, which will significantly improve the quality of life for women burdened by recurrent UTI and enable better antibiotic stewardship.</jats:p><jats:sec><jats:title>Importance</jats:title><jats:p>Urinary tract infections (UTI) are among the most common bacterial infection in humans, affecting half of all women at least once during their lifetimes. The rise in antibiotic resistance and health care costs emphasizes the need to develop a vaccine against the most common UTI pathogen, <jats:italic>Escherichia coli.</jats:italic> Vaccinating mice intranasally with a detoxified heat-labile enterotoxin and two surface exposed receptors, Hma or IutA, significantly reduced bacterial burden in the bladder. This work highlights progress in the development of a UTI vaccine formulated with adjuvants suitable for human use and antigens that encode outer membrane iron receptors required for infection in the iron-limited urinary tract.</jats:p></jats:sec>

Progress toward the development of an effective vaccine for Extraintestinal pathogenicE. coli(ExPEC): The application of the multiple-protein subunits vaccine in different murine models

“…Non-fimbrial-based vaccines, such as adhesin FdeC [58], PapG fimbrial adhesin [56], and Dr fimbriae [55], have also demonstrated protection against UTIs in vivo [57]. Moreover, four defined E. coli iron acquisition antigens (IroN, lutA, IreA, and FyuA) [66][67][68][69] and siderophores (iron-chelating compounds) [70] have generated strong immune responses, showing potential as ExPEC vaccine candidates [64,65]. Similarity, some toxin-based vaccine attempts, such as insoluble α-hemolysin [71,72], and auto-transporter toxin Vat [73], have exhibited some protection against ExPEC infection in vivo.…”